MacroGenics Announces Participation in Two Upcoming Investor Conferences
ROCKVILLE, MD, Sept. 26, 2018 (GLOBE NEWSWIRE) --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in two investor conferences in early October. These conferences include:
- Cantor Fitzgerald Global Healthcare Conference – MacroGenics’ management will participate in the conference and provide a corporate update on October 2, 2018, at 10:20 a.m. ET in New York City.
- Leerink Partners Roundtable Series: Rare Disease & Oncology – MacroGenics’ management will participate in the conference, including a fireside chat on October 3, 2018, at 3:30 p.m. ET in New York City.
Webcasts of both presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, firstname.lastname@example.orgKaren Sharma, Senior Vice President
MacDougall Biomedical Communications
Source: MacroGenics, Inc.